Shree PacetronixBOM:527005 -0.19%81 EBITDA Margin % is 31.24% as of Mar. 2026, which is 120% above its 10-year median of 14.21. GuruFocus rates BOM:527005 with a GF Score™ of 81/100 and a GF Value™ of ₹163.21 (Modestly Undervalued). Among 817 Medical Devices & Instruments companies, Shree Pacetronix ranks better than 84.21% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Shree Pacetronix's EBITDA for the
three
months ended in Mar. 2026 was ₹16.8 Mil. Shree Pacetronix's Revenue for the
three
months ended in Mar. 2026 was ₹53.7 Mil. Therefore, Shree Pacetronix's EBITDA margin for the quarter that ended in Mar. 2026 was 31.24%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shree Pacetronix EBITDA Margin % Related Terms
Shree Pacetronix EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Shree Pacetronix's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:527005 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Shree Pacetronix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Pacetronix EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shree Pacetronix's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shree Pacetronix's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Pacetronix (BOM:527005) has a EBITDA Margin % of 31.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shree Pacetronix and its competitors. This is 120% above median its historical median of 14.21. Over the past decade, Shree Pacetronix's EBITDA Margin % has ranged from 8.46 to 27.13. According to the industry distribution chart, Shree Pacetronix ranks #129 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 15.8%.
Is Shree Pacetronix's EBITDA Margin % too high?
Shree Pacetronix's current EBITDA Margin % of 31.24% is 120% above median its 10-year median of 14.21. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 27.13. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Shree Pacetronix's value of 31.24% is 319.9% above this industry median. Based on the distribution chart, Shree Pacetronix ranks #129 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shree Pacetronix has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shree Pacetronix's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shree Pacetronix ranks #129 out of 817 companies for EBITDA Margin %. This places Shree Pacetronix in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.44. Shree Pacetronix's value of 31.24% is 319.9% above this benchmark. Historically, Shree Pacetronix's own EBITDA Margin % has ranged from 8.46 to 27.13 over the past decade. While the company's 10-year median is 14.21 vs. the industry median of 7.44, Shree Pacetronix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shree Pacetronix's current EBITDA Margin % of 31.24% is 319.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shree Pacetronix and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Pacetronix's current EBITDA Margin % is 31.24%, which is 120% above median its own 10-year median of 14.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Pacetronix stock overvalued right now?
Based on GuruFocus' analysis, Shree Pacetronix (BOM:527005) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹163.21, compared to a current price of ₹130.05 — trading 20.3% below its estimated fair value. The current EBITDA Margin % is 31.24%, which is 120% above median its 10-year median of 14.21 and 319.9% above the Medical Devices & Instruments industry median of 7.44. Shree Pacetronix's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shree Pacetronix (BOM:527005), the current EBITDA Margin % is 31.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Pacetronix (BOM:527005) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Pacetronix stock appears to be undervalued.
The current stock price of ₹130.05 is trading 20.3% below its estimated GF Value™ of ₹163.21.
GuruFocus considers Shree Pacetronix to be Modestly Undervalued.
Key valuation signals for BOM:527005:
EBITDA Margin %: 31.24% (120% above median its 10-year median of 14.21)
GF Value™: ₹163.21 vs. price of ₹130.05 (20.3% below fair value)
Industry Position: 319.9% above the Medical Devices & Instruments median (#129 of 817)
No single metric tells the full story. See the BOM:527005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Pacetronix Ltd is engaged in the manufacturing of medical and surgical equipment and orthopedic appliances. It is in the business of manufacturing and selling Implantable Cardiac Pacemakers. Pacemakers are anti-bradycardia implantable devices intended for permanent ventricular or atrial pacing applications. The Company is engaged in only one segment i.e. Life Saving Devices. It sells its life-saving devices in India and internationally, of which the majority of revenue is generated from the sales made in India.
81GF Score
Get the complete analysis for BOM:527005
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:527005 has been successfully added to your 
